| Objective To observe the clinical efficacy of parathyroid hormone (1-34, PTH) combined with vitamin K2 (VK2) in patients with postmenopausal osteoporosis. Methods A total of 120 patients with postmenopausal osteoporosis who were treated in our hospital from May 2014 to February 2016 were selected and divided into 3 groups according to the time of admission: VK2 group, PTH group, and combination therapy group. Forty patients in PTH group received subcutaneous injection of 20μg teriparatide, once a day, 6 months. Thirty-nine patients in VK2 group received 45mg/d soft capsule of tetranaphthalenone orally, 3 times a day, for 12 months. Forty patients in combination therapy group received teriparatide combined with tetramethylene naphthoquinone soft capsules. After the treatment, the changes of bone mineral density (BMD) of the lumbar spine and hip, blood calcium and phosphorus, changes of bone biophosphate (BALP), type I collagen N-terminal peptide/creatinine (NTX/Cr) were compared among the 3 groups. The incidence of adverse reaction was also compared. Results After 6 and 12 months of the treatment, BMD in the 3 groups was significantly improved (P<0.05), and BMD in the combination therapy group was significantly better than that in the PTH and VK2 group (P<0.05) at the same time point. After 12 months of drug treatment, serum BALP and NTX / Cr were significantly changed than those before the treatment (P<0.05), and those in the combination therapy group was significantly better than in VK2 and PTH group (P<0.05) at the same time point. There was no significant difference in the incidence of adverse drug reactions among the 3 groups (P>0.05). Conclusion PTH and VK2 have significant effect on postmenopausal osteoporosis, and the combination therapy shows a better clinical efficacy. |